192 related articles for article (PubMed ID: 17212661)
1. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
5. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
6. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
7. p53 and HER-2/neu overexpression in ovarian borderline tumors.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
[TBL] [Abstract][Full Text] [Related]
8. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
9. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
Mayr D; Kanitz V; Amann G; Engel J; Burges A; Löhrs U; Diebold J
Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
[TBL] [Abstract][Full Text] [Related]
11. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
13. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
14. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
15. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
[No Abstract] [Full Text] [Related]
18. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P
Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study.
Verri E; Guglielmini P; Puntoni M; Perdelli L; Papadia A; Lorenzi P; Rubagotti A; Ragni N; Boccardo F
Oncology; 2005; 68(2-3):154-61. PubMed ID: 16020953
[TBL] [Abstract][Full Text] [Related]
20. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
